Treatment Preference for Opioid Use Disorder Among People Who Are Incarcerated

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2021 Dec 21

PMID 34930575

Citations 11

Authors

Eliana Kaplowitz

Ashley Q Truong

Justin Berk

Rosemarie A Martin

Jennifer G Clarke

Morgan Wieck

Josiah Rich

Lauren Brinkley-Rubinstein

Affiliations

Soon will be listed here.

Abstract

Introduction: The devastating overdose crisis remains a leading cause of death in the United States, especially among individuals involved in the criminal legal system. Currently, three classes (opioid agonist, partial agonist-antagonist, and antagonist) of FDA-approved medications for opioid use disorder (MOUD) exist, yet few correctional settings offer any medication treatment for people who are incarcerated. Facilities that do often provide only one medication.

Methods: We conducted 40 semi-structured qualitative interviews with individuals receiving MOUD incarcerated at the Rhode Island Department of Corrections.

Results: Results from this study indicate that people who are incarcerated have preferences for certain types of MOUD. Individuals' preferences were influenced by medication side effects, route of administration, delivery in the community, and stigma.

Conclusion: MOUD programs in the community and in correctional settings should use a patient-centered approach that allows choice of medication by offering all FDA-approved MOUD treatment options.

Citing Articles

"They talked to me like I was dirt under their feet:" Treatment and withdrawal experiences of incarcerated pregnant people with opioid use disorder in four U.S. states.

Sufrin C, Ziv T, Dayton L, Latkin C, Kramer C SSM Qual Res Health. 2025; 6.

PMID: 39748911 PMC: 11694624. DOI: 10.1016/j.ssmqr.2024.100453.

Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019.

Bovell-Ammon B, Yan S, Dunn D, Evans E, Friedmann P, Walley A Drug Alcohol Depend. 2024; 262:111392.

PMID: 39029371 PMC: 11348723. DOI: 10.1016/j.drugalcdep.2024.111392.

Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial.

Balter D, Puglisi L, Dziura J, Fiellin D, Howell B J Subst Use Addict Treat. 2024; 164:209438.

PMID: 38857827 PMC: 11300157. DOI: 10.1016/j.josat.2024.209438.

Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study.

Saunders E, Budney A, Cavazos-Rehg P, Scherer E, Bell K, John D J Subst Use Addict Treat. 2024; 163:209383.

PMID: 38670531 PMC: 11180569. DOI: 10.1016/j.josat.2024.209383.

Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes.

Bovell-Ammon B, Yan S, Dunn D, Evans E, Friedmann P, Walley A JAMA Netw Open. 2024; 7(3):e242732.

PMID: 38497959 PMC: 10949092. DOI: 10.1001/jamanetworkopen.2024.2732.

References

Wakeman S, Larochelle M, Ameli O, Chaisson C, McPheeters J, Crown W . Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020; 3(2):e1920622. PMC: 11143463. DOI: 10.1001/jamanetworkopen.2019.20622. View

Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R . The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010; 39(4):340-52. DOI: 10.1016/j.jsat.2010.07.009. View

Muthulingam D, Bia J, Madden L, Farnum S, Barry D, Altice F . Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. J Subst Abuse Treat. 2019; 100:18-28. PMC: 6432946. DOI: 10.1016/j.jsat.2019.01.019. View

Randall-Kosich O, Andraka-Christou B, Totaram R, Alamo J, Nadig M . Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder. J Addict Med. 2019; 14(4):e44-e52. DOI: 10.1097/ADM.0000000000000584. View

Green T, Clarke J, Brinkley-Rubinstein L, Marshall B, Alexander-Scott N, Boss R . Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. JAMA Psychiatry. 2018; 75(4):405-407. PMC: 5875331. DOI: 10.1001/jamapsychiatry.2017.4614. View

ODonnell J, Gladden R, Mattson C, Hunter C, Davis N . Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants - 24 States and the District of Columbia, January-June 2019. MMWR Morb Mortal Wkly Rep. 2020; 69(35):1189-1197. PMC: 7470457. DOI: 10.15585/mmwr.mm6935a1. View

Rich J, McKenzie M, Larney S, Wong J, Tran L, Clarke J . Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015; 386(9991):350-9. PMC: 4522212. DOI: 10.1016/S0140-6736(14)62338-2. View

Cummings J, Wen H, Ko M, Druss B . Race/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiatry. 2013; 71(2):190-6. PMC: 4039494. DOI: 10.1001/jamapsychiatry.2013.3575. View

Uebelacker L, Bailey G, Herman D, Anderson B, Stein M . Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification. J Subst Abuse Treat. 2016; 66:48-53. PMC: 4892369. DOI: 10.1016/j.jsat.2016.02.009. View

10.

Joosten E, de Jong C, de Weert-van Oene G, Sensky T, van der Staak C . Shared decision-making reduces drug use and psychiatric severity in substance-dependent patients. Psychother Psychosom. 2009; 78(4):245-53. DOI: 10.1159/000219524. View

11.

Huhn A, Tompkins D, Dunn K . The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017; 180:279-285. PMC: 5648596. DOI: 10.1016/j.drugalcdep.2017.08.019. View

12.

Fiellin D, Schottenfeld R, Cutter C, Moore B, Barry D, OConnor P . Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014; 174(12):1947-54. PMC: 6167926. DOI: 10.1001/jamainternmed.2014.5302. View

13.

Brinkley-Rubinstein L, Peterson M, Clarke J, Macmadu A, Truong A, Pognon K . The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. Drug Alcohol Depend. 2019; 205:107514. PMC: 10347877. DOI: 10.1016/j.drugalcdep.2019.06.016. View

14.

Teruya C, Schwartz R, Mitchell S, Hasson A, Thomas C, Buoncristiani S . Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014; 46(5):412-26. PMC: 4220245. DOI: 10.1080/02791072.2014.921743. View

15.

Saloner B, Parish K, Ward J, DiLaura G, Dolovich S . COVID-19 Cases and Deaths in Federal and State Prisons. JAMA. 2020; 324(6):602-603. PMC: 7344796. DOI: 10.1001/jama.2020.12528. View

16.

Tiako M . Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. J Subst Abuse Treat. 2020; 122:108214. PMC: 7685132. DOI: 10.1016/j.jsat.2020.108214. View

17.

Mooney L, Valdez J, Cousins S, Yoo C, Zhu Y, Hser Y . Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results. J Subst Abuse Treat. 2019; 108:115-122. PMC: 7397558. DOI: 10.1016/j.jsat.2019.08.006. View

18.

Nijhawan A . Infectious Diseases and the Criminal Justice System. Am J Med Sci. 2016; 352(4):399-407. PMC: 5119815. DOI: 10.1016/j.amjms.2016.05.020. View

19.

Friedrichs A, Spies M, Harter M, Buchholz A . Patient Preferences and Shared Decision Making in the Treatment of Substance Use Disorders: A Systematic Review of the Literature. PLoS One. 2016; 11(1):e0145817. PMC: 4701396. DOI: 10.1371/journal.pone.0145817. View

20.

Gryczynski J, Jaffe J, Schwartz R, Dusek K, Gugsa N, Monroe C . Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013; 22(3):285-91. PMC: 4215541. DOI: 10.1111/j.1521-0391.2012.12004.x. View